Palmitoyl tripeptide-38 (Matrixyl synthe'6)

Not FDA-approved

Last verified: October 30, 2026

At a glance

FDA approval Not FDA-approved No record in Drugs@FDA

Randomized controlled trials 0 of 3 publications on PubMed

Registered clinical trials 1 0 active

Adverse event reports 0 0 classified as serious

Palmitoyl tripeptide-38 (Matrixyl synthe'6) is not an FDA-approved drug: Drugs@FDA has no record of it.
PubMed lists 3 publications mentioning it, including 0 randomized controlled trials and 0 animal-only studies.
ClinicalTrials.gov lists 1 registered study testing it (0 active).
FDA’s adverse event system (FAERS) has no reports mentioning it.

Research topics

Skin Aging 3
Face 2
Administration, Cutaneous 1
Aging 1
Cellular Senescence 1
Cosmeceuticals 1
Creatine 1
Dermatologic Agents 1
Elasticity 1
Esthetics 1

Most frequent MeSH subject headings in the latest PubMed records (English, as indexed).

Regulatory status

Drugs@FDA applications

No application found in Drugs@FDA, FDA's database of approved drugs.

Source: Drugs@FDA (openFDA) · verified October 30, 2026 · API query

FDA compounding safety list

Not on FDA's list of bulk drug substances that may present significant safety risks in compounding.

Source: FDA.gov — Category 2 bulk drug substances · verified October 30, 2026

Removal of a substance from a regulatory list does not mean it has been approved. A "research use only" label does not make a product safe or legal for human use.

Scientific publications

All publications 3
Human (MeSH) 3
Animal only 0
Clinical trials 1
Randomized controlled trials 0
Systematic reviews & meta-analyses 0
Case reports 0
Retracted 0

Counts are PubMed records that mention the peptide in the title or abstract. Categories overlap, and a mention is not the same as testing the peptide as a treatment. Each number opens the exact PubMed search. Effects seen in laboratory or animal studies may not occur in humans. A registered clinical trial does not show that a substance is effective or safe.

Latest publications

A serum containing vitamins C & E and a matrix-repair tripeptide reduces facial signs of aging as evidenced by Primos® analysis and frequently repeated auto-perception. Human study 2020 Journal of cosmetic dermatology
Biorevitalizing effect of a novel facial serum containing apple stem cell extract, pro-collagen lipopeptide, creatine, and urea on skin aging signs. Human study 2016 Journal of cosmetic dermatology
An Open Label Clinical Trial of a Multi-Ingredient Anti-Aging Moisturizer Designed to Improve the Appearance of Facial Skin. Clinical trial 2015 Journal of drugs in dermatology : JDD

Source: PubMed (NCBI) · verified October 30, 2026

Clinical trials

Registered: 1
Active: 0
With posted results: 0

Conditions studied

Photoaging 1
Skin Aging 1

Study	Status	Phase	Start
AI-Personalized Skincare Regimen for Facial Photoaging in Women NCT07879833 MDalgorithms Inc.	Completed	N/A	September 30, 2025

All 1 study on ClinicalTrials.gov ↗

Source: ClinicalTrials.gov · verified October 30, 2026

Adverse event reports

No FAERS reports mention this peptide.

Source: FDA FAERS · verified October 30, 2026 · API query

Change history

No changes since monitoring began on October 30, 2026.